Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Neuron23 has raised $2.5M in total funding. The most recent round was Grant. The last funding was announced in June 2026.
Neuron23's investors include Kleiner Perkins, Perceptive Advisors, Blue Owl, Redmile Group, Michael J. Fox Foundation.
Neuron23 is headquartered in San Francisco, United States.
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Neuron23 is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neuron23 — Funding & Investors." VCBacked, June 17, 2026, https://www.vcbacked.co/company/neuron23. Accessed August 13, 2026.
VCBacked. (2026). Neuron23 — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/neuron23
{{cite web |title=Neuron23 — Funding & Investors |url=https://www.vcbacked.co/company/neuron23 |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated